Ameriprise’s Nuvalent NUVL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$57.8M Sell
563,768
-530
-0.1% -$54K 0.01% 797
2025
Q4
$56.8M Buy
564,298
+37,248
+7% +$3.67M 0.01% 810
2025
Q3
$45.6M Buy
527,050
+42,707
+9% +$3.38M 0.01% 938
2025
Q2
$37M Buy
484,343
+204,002
+73% +$14.9M 0.01% 1021
2025
Q1
$19.9M Buy
280,341
+42,785
+18% +$3.35M 0.01% 1321
2024
Q4
$18.6M Buy
237,556
+171,725
+261% +$16M ﹤0.01% 1380
2024
Q3
$6.73M Buy
+65,831
New +$5.46M ﹤0.01% 2158
2023
Q4
Sell
-211,923
Closed -$9.74M 3954
2023
Q3
$9.74M Buy
+211,923
New +$9.41M ﹤0.01% 1724

Other funds holding NUVL

Ameriprise's NUVL Position: Q1 2026 in Review

Ameriprise reduced its Nuvalent (NUVL) stake by 0.09% in Q1 2026, selling an estimated $54K and leaving 563,768 shares worth $57.8M. The position accounts for 0.01% of the portfolio, ranked #797.

Ameriprise first reported a position in NUVL in Q3 2023 and has held it in 8 quarters since. 263 funds tracked by Wall St. Rank hold NUVL as of Q1 2026.

  • Ameriprise held 563,768 shares of Nuvalent worth $57.8M as of Q1 2026.
  • Ameriprise sold 530 Nuvalent shares in Q1 2026, an estimated $54K.
  • Nuvalent made up 0.01% of Ameriprise's portfolio in Q1 2026, its #797 holding.
  • Ameriprise first reported a position in Nuvalent in Q3 2023 and has held it in 8 quarters since.
  • 263 funds tracked by Wall St. Rank held Nuvalent as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.